Health Economics & Reimbursement
Will psychedelic therapy save money or break budgets? The economic studies are strikingly upbeat, with headline claims that MDMA therapy for trauma is "cost-saving" and that scaling it could save billions. But almost every one of those numbers is the output of a model, a spreadsheet built on assumptions about how well the therapy works, how long the benefit lasts, how cheaply it can be delivered, and what it will cost, rather than a measured economic result. Change the assumptions and the conclusions move dramatically: the same drug can look cost-saving over thirty years and merely acceptable over one, cost-effective to society but unaffordable to a health system. The molecule is cheap; the hours of skilled therapy around it are not, and that is what really drives the sums. Only ketamine has real-world cost data and actual insurance coverage; for the classic psychedelics, the economics, like the reimbursement, are still almost entirely on paper.
Data updated
Key Insights
- 1
This is an economics page, not a condition or a treatment. It asks whether psychedelic therapy is cost-effective, how it might be paid for, and what it would cost a health system, rather than whether it works.
- 2
Almost every economic headline is a model, not a measurement. The "cost-saving" and "cost-effective" claims come from decision-analytic projections built on assumptions about efficacy, durability, scaling and price, not from observed budget outcomes.
- 3
Durability is the load-bearing assumption. Cost-effectiveness depends overwhelmingly on how long the benefit lasts: the same MDMA model looks cost-saving over a thirty-year horizon but far less impressive if the benefit is assumed to fade after a year, and relapse or repeat dosing can erase the advantage entirely.
- 4
The therapy, not the drug, is the cost. The molecule is cheap; the many hours of skilled clinician time around each dose are what dominate the price, which is why the economics swing on the assumed cost of therapy and on whether it can be delivered more cheaply, for example in groups.
- 5
Reimbursement barely exists for classic psychedelics. Only ketamine and esketamine are actually covered and priced in the real world; psilocybin and MDMA economics are pre-market projections, and health-technology assessors will demand active-comparator evidence the field does not yet have.
By the numbers
- 7
- Trials tracked
- 30
- Papers tracked
- 959
- Trial participants
as of July 2026
as of July 2026
as of July 2026
Research Landscape
What the 7 registered trials connected to Health Economics & Reimbursement look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 7 Health Economics & Reimbursement trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
About Health Economics & Reimbursement
Health economics and reimbursement is not a condition or a treatment; it is the question of money. Whatever a psychedelic therapy does for a patient, a health system has to decide whether it is worth paying for, how it compares with existing treatments per pound or dollar spent, what it would cost to provide at scale, and whether insurers or governments will cover it. This page is about that economic case, and about a crucial distinction that is easy to lose: the difference between what the models project and what has actually been measured.
The headline findings here are unusually optimistic. Several studies conclude that MDMA-assisted therapy for trauma is not just cost-effective but cost-saving, and that scaling psychedelic therapy could save health systems billions. Those are striking claims, and they are also, almost without exception, the outputs of decision-analytic models, structured spreadsheets that take assumptions about how well a therapy works, how long the benefit lasts, how cheaply it can be delivered and what it will be priced at, and calculate a cost per unit of health gained. The results are only as good as those assumptions, and the assumptions are where the real uncertainty lives.
The single most important idea to carry through this page is that a favourable cost-effectiveness number is a projection, not a fact. Change the time horizon, the durability assumption, the comparator or the assumed price, and the same therapy can flip from "dominant" to "not worth it". The economics are inseparable from the practical questions of how the therapy is actually delivered and how it reaches a population, and they should be read as careful arguments about what might be true under stated conditions, not as evidence that psychedelic therapy will, in reality, save money.
Approach & Methods
Because there is no condition here, the relevant "evidence" is the small set of economic models, and they share a revealing feature: their conclusions swing on the assumptions, not the drug. A US model of psilocybin for treatment-resistant depression illustrates this perfectly: it reported a reasonable cost per QALY, but its cost-effectiveness went from a 1% probability at an assumed $10,000 therapy cost to 95% at $3,000[1]. A UK model reached a similar verdict from the other direction, finding psilocybin cost-effective only if therapist costs were halved and the price held to a few hundred pounds[2]. In both cases the economics are a function of the assumed price and labour cost, not an intrinsic property of the treatment.
The same assumption-dependence runs through the most optimistic literature. MDMA-assisted therapy for PTSD is repeatedly modelled as cost-saving over a thirty-year horizon[3], but the same kind of model shows that if the benefit is assumed to last only one year, the figure becomes a far more ordinary cost per QALY[4], and a more conservative five-year analysis lands at a respectable but not spectacular cost-effectiveness ratio[5]. The honest reading of the "standard" evidence is that the favourable numbers are real model outputs under stated assumptions, and that the assumptions, especially about how long the benefit lasts, are doing most of the work.
This report summarises what Blossom’s database shows about the health economics and reimbursement of psychedelic therapies, whether they are worth the money, who would pay, and what they would cost. It is worth being clear what kind of page this is. It is not a condition page and not a treatment. It is about money and models, and its central, recurring message is a warning: almost every economic conclusion here is a projection built on assumptions, not a measured result.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a recommendation to take psychedelics or a statement about what any treatment will cost you. The figures below come from health-economic models, which are useful but assumption-laden tools, and from a reimbursement landscape that, for classic psychedelics, barely exists yet. Read the numbers as carefully-reasoned scenarios, not as facts about the future.
The headlines, and what they really are
The economic literature on psychedelic therapy is unusually upbeat. MDMA-assisted therapy for PTSD has been modelled as cost-saving, with projected net savings of well over a hundred million dollars per thousand patients across a thirty-year horizon[1], and a model of scaling it in one country projected billions in societal savings[2]. Psilocybin for depression has been found cost-effective in both US and UK analyses. Taken at face value, this looks like a settled, favourable economic case.
But these are not measurements; they are models. A health-economic model is a structured calculation that takes assumptions, how effective the therapy is, how long the benefit lasts, how much the therapy costs to deliver, what the drug is priced at, what time horizon to use, and produces a cost per unit of health gained. The output is only as trustworthy as the inputs, and in this field the inputs are uncertain and, in places, optimistic. The single most important habit for reading this topic is to ask, of every striking number, what was assumed to get here?
Durability: the assumption that decides everything
If there is one assumption that makes or breaks the economics, it is durability, how long a single course of therapy keeps working. The cost-saving headlines depend on the benefit lasting years. The clearest demonstration is internal to the models themselves: an MDMA analysis that looks cost-saving over thirty years shows that if you instead assume the benefit ceases after one year, the result becomes an ordinary cost per QALY of around $26,000[3], and the Ukraine projection explicitly assumes three years of sustained efficacy[2]. A more conservative five-year MDMA model lands at a respectable but unspectacular ratio[4].
This matters enormously because durability is exactly what the evidence does not yet establish. Long-term follow-up is scarce, relapse is common in the conditions being treated, and some of these therapies, ketamine especially, are not one-shot cures but require repeated dosing, which multiplies the cost. A model that assumes a single session buys years of remission will look cheap; if the reality is periodic re-treatment, the economics look very different. Until there is real long-term outcome data, the favourable cost-effectiveness conclusions rest on a foundation that has not been built.
The drug is cheap; the therapy is not
A second crucial point is what actually costs money. It is not the drug. A dose of psilocybin or generic ketamine is inexpensive; what is expensive is the many hours of skilled clinician time, screening, preparation, a long supervised dosing session, and integration, wrapped around it. This is why the economics swing so hard on the assumed cost of therapy. The US psilocybin model is the clearest example: its cost-effectiveness collapsed from near-certain at a $3,000 therapy cost to almost impossible at $10,000[5], and the UK model found the therapy viable only if therapist costs were cut in half[6]. The molecule is a rounding error; the labour is the budget.
This has a direct consequence for the whole optimistic case: it depends on delivering the labour-intensive therapy far more cheaply than trials do, for instance by treating people in groups. That is plausible but unproven, and it ties the economics inseparably to the unsolved problems of delivery and workforce. An economic model that assumes cheap, scalable delivery is, in effect, assuming away the field’s single hardest practical problem.
Perspective, comparator and the art of the favourable number
Health-economic results are notoriously sensitive to choices that are easy to overlook, and this literature shows it. Whose costs you count, society’s or a health system’s, can flip a verdict: esketamine is cost-effective from a societal perspective but well over the affordability threshold from a health-system one[7]. What you compare against matters just as much: branded esketamine is dominated by cheaper generic ketamine when the comparison is made honestly[8], and a ketamine analysis can read as "dominant" or as costing a quarter of a million dollars per QALY depending only on whether you include the comparator’s costs[9].
None of this means the models are dishonest; it means a single cost-effectiveness number is a scenario, not a fact, and that framing choices, often made by sponsor-adjacent analysts, tend to push toward the favourable. The esketamine cost-per-remitter studies, framed from an industry perspective[10], are useful but not neutral. The discipline this topic demands is to treat every ICER as one point in a wide range, and to ask who chose the assumptions and which way they lean.
Reimbursement: real for ketamine, hypothetical for the rest
For all the modelling, the practical reality is that classic psychedelics are reimbursed almost nowhere. Only ketamine and esketamine have actual coverage, pricing and real-world cost data; psilocybin and MDMA economics are entirely pre-market projections. And the path to reimbursement is harder than the optimistic models imply: health-technology assessment bodies such as NICE typically demand trials against active comparators, which the psychedelic field has barely conducted[11], compounded by the genuine difficulty of valuing a drug-plus-psychotherapy package. The gap between "modelled as cost-saving" and "actually reimbursed" is wide and will not close quickly.
There is also a demand-side reality check. When patients themselves are asked what they would pay, the answer is sobering: in one survey, users considered around $70-80 an hour reasonable, well below current market projections[12]. If the labour-intensive model prices these therapies far above what patients will pay and payers will cover, the cost-effectiveness models, however favourable, describe a treatment that much of the population still cannot access, which turns an economic question back into a question of equity and public health.
Reading this honestly
So how should you read the economics of psychedelic therapy? As a set of careful, useful, but assumption-driven projections that are widely mistaken for established facts. The favourable numbers are real model outputs, and the cost-saving potential is genuine in principle: if these therapies are durable and can be delivered cheaply, the case is strong. But every one of those "ifs" is unsettled. The cost-saving headlines depend on benefits lasting years, which has not been shown; on delivering expensive therapy cheaply, which has not been demonstrated; and on prices and perspectives that can be tuned to almost any conclusion. Only ketamine has real-world cost and reimbursement data, and even there the cheaper generic often wins. The most useful thing this literature offers an honest reader is a translation: when you see "psychedelic therapy is cost-saving", read "a model projects it could be cost-saving, if it works as assumed, lasts as long as assumed, is delivered as cheaply as assumed, and is priced as assumed". That is a meaningfully different, and more honest, claim, and it is the one the evidence actually supports.
Free Account Narrative Report
Create a free Blossom account to read this narrative synthesis.
Research Outlook
The decisive variable for the field’s economic future is durability, and it is also the least settled. Every cost-saving conclusion depends on the benefit of a single course of therapy lasting years, the Ukraine MDMA model, for instance, explicitly assumes three years of sustained efficacy[1]. If benefits fade faster, or if patients need repeat or maintenance dosing (as ketamine patients typically do), the arithmetic that makes these therapies look cheap collapses. The most valuable economic research the field could do is therefore not another model but real long-term follow-up: actual data on how long remission lasts and how often treatment must be repeated.
The other frontier is reimbursement, and here the gap between ketamine and the classic psychedelics is stark. Esketamine is actually covered and priced, which generates real-world economic evidence, including the uncomfortable finding that the branded product is dominated by far cheaper generic ketamine from a health-system perspective[2]. Classic psychedelics, by contrast, are reimbursed essentially nowhere, and face a structural hurdle: health-technology assessors typically demand active-comparator trials that the psychedelic field has barely run[3]. The honest outlook is that the economic case will be made or broken not by more optimistic modelling but by long-term durability data and by clearing reimbursement bars the field has not yet reached.
Industrial Landscape
The economics of psychedelic therapy are shaped by who builds the models and who pays the bills. A notable share of the cost-effectiveness literature is sponsor-adjacent: the most optimistic MDMA analyses come from within the advocacy and development ecosystem, and the esketamine cost-per-remitter studies are framed from an industry perspective[1]. That does not make them wrong, but it means the headline framing tends toward favourability, and independent analyses are few. The real decision-makers, the insurers, governments and health-technology bodies, apply a colder lens, and the recurring lesson is that a therapy can look cost-effective to society while being unaffordable to the payer who actually writes the cheque, as the esketamine cost-utility work shows when it flips from acceptable to far-above-threshold depending on perspective[2].
For an honest broker, health economics is where optimism is most easily dressed in the authority of numbers, and the responsible posture is to read the numbers as scenarios rather than conclusions. The favourable ICERs are genuine outputs of careful models, and the cost-saving potential, if the therapies are durable and can be delivered cheaply, is real in principle. But every figure rests on assumptions about durability, delivery cost, price and perspective that can be tuned to almost any answer, the same ketamine analysis is "dominant" or wildly expensive depending only on whether control-arm costs are counted[3]. The most useful framing keeps three facts in view: these are models, not realised outcomes; durability is the assumption that decides everything; and patients themselves say they would pay far less than the models and the market assume[4], a gap that the question of who can actually afford and access these therapies will ultimately have to close.
Blossom Pro Structured Analysis
Unlock compound evidence, clinical outlook, and stakeholder analysis.
Quick Indicators
Organisations
Search →OPEN Foundation
OPEN Foundation is a Dutch non-profit organisation based in Amsterdam. It focuses on psychedelic research, education, conferences, workshops, and continuing education courses. Its activities aim to help integrate psychedelics ethically and responsibly into science, healthcare, and society.
University Medical Center Groningen
The University Medical Center Groningen (UMCG) is the academic hospital affiliated with the University of Groningen, providing tertiary and specialized patient care while conducting medical research and education. It is one of the largest university hospitals in the Netherlands and serves as the main academic medical center for the northern Netherlands.
University of Exeter
The University of Exeter is a public research university located in Exeter, England. It operates multiple campuses including Streatham and St Luke’s in Exeter and a campus at Penryn in Cornwall.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
University of Copenhagen
The Neurobiology Research Unit (NRU) at Copenhagen University Hospital has been carrying out clinical and preclinical research with psychedelics since 2017. The team at the NRU utilizes various neuroimaging techniques to better understand how psychedelics exert their effects on the brain. They have published numerous peer-reviewed articles on psychedelics and facilitated numerous medium-dose psilocybin sessions. The NRU is led by Professor Gitte Moos Knudsen.
29k International AB
29k International AB is a Swedish non-profit tech foundation offering a free mental health app with science-based psychological tools and peer support programs, partnering with institutions including Karolinska Institute and Harvard University. The organization has been involved in clinical research as a digital therapeutic support platform in studies exploring mental health outcomes alongside psychedelic and other novel interventions.
American Psychiatric Association
The American Psychiatric Association is the national medical specialty society for psychiatry in the United States, with headquarters in Washington, DC and a membership base of psychiatric physicians. It serves psychiatrists and the broader mental health field through official position statements, clinical guidance, journals, and public policy communications. Its core activity is to represent psychiatry in clinical, professional, and policy discussions affecting mental health care. APA has an explicit, cautious stance on psychedelics and empathogens in mental health care. Its 2022 position statement says there is not yet adequate scientific evidence to endorse use outside approved investigational studies, while supporting continued research under strong scientific and regulatory standards. In 2024 APA also submitted comments to FDA on MDMA and in 2026 it publicly welcomed federal investment in psychedelic research while reiterating the need for controlled studies and patient protections.
Bispebjerg Hospital
Bispebjerg Hospital is a major Copenhagen university hospital and the coordinating site for PsyPal, the EU-funded multi-centre trial investigating psilocybin-assisted therapy for anxiety and existential distress in patients with ALS—the first European publicly-funded psychedelic trial of its kind. Affiliated with the University of Copenhagen, the hospital leads Nordic clinical research into psychedelic-assisted therapies for neurological and palliative conditions.
Canisius-Wilhelmina Hospital
Canisius-Wilhelmina Hospital (CWZ) is a major teaching hospital in Nijmegen, Netherlands, whose Department of Neurology has contributed to psychedelic research including an evidence-based review of LSD and psilocybin for chronic pain management, examining serotonin-2A receptor-mediated neuroplastic mechanisms. Situated in the Netherlands—one of Europe’s most active countries for psychedelic research—CWZ participates in neurological research exploring psychedelic compounds as therapeutic agents for pain and psychiatric conditions.
CTC Clinical Trial Consultants AB
Full-service CRO with in-house research units in Sweden and the Netherlands. Psychedelic-specific evidence remains weaker than its general CNS and early-phase site-network capability.
European Association for Palliative Care (EAPC)
The European Association for Palliative Care is a European professional association based in Milan, Italy, with members and collective member associations across Europe. Its stated purpose is to promote palliative care in Europe and to support people working in or interested in palliative care at scientific, clinical, and social levels. Its core activities include education, research, publications, and convening multidisciplinary professionals, patients, and volunteers in the field. EAPC is adjacent to psychedelic medicine through its palliative care role and participation in PsyPal, an EU-funded psilocybin trial focused on psychological distress in palliative patients with COPD, atypical Parkinsonian disorders, ALS, and multiple sclerosis. Public sources describe EAPC as a consortium partner in a broader European effort to build evidence for psychedelic therapy in palliative care and to support future ethical, cost-effective implementation. This makes EAPC relevant to researchers, clinicians, funders, and policy groups working on evidence generation, clinical integration, and patient-centered access in serious illness care.
People
Search →Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Kruti Joshi
Employee at Janssen Scientific Affairs, LLC
Joshi appears to be a Janssen-affiliated researcher coauthoring multiple real-world evidence studies on esketamine access, barriers, utilization, and economic outcomes in treatment-resistant depression.
Michael Ashton
Professor of Clinical Pharmacology at the University of Gothenburg
He is a pharmacometrics and clinical pharmacology researcher whose work has been used in psychedelic studies on DMT pharmacokinetics, pharmacodynamics, EEG effects, and psychedelic intensity modeling.
Scott Tyler Aaronson
Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt; Adjunct Professor of Psychiatry, University of Maryland School of Medicine
He is a leading psychiatrist in treatment-resistant depression and a key investigator on psilocybin studies, including work on preparation, dosing, outcomes, and mechanisms of psychedelic-assisted therapy.
Mark Andrew Frye
Chair, Department of Psychiatry and Psychology, Mayo Clinic (Rochester, Minnesota)
He is a leading mood-disorders psychiatrist whose work has helped shape the clinical evidence base and consensus guidance for ketamine in depression.
Jack Stroud
Clinical Psychologist; Trainee Clinical Psychologist at University College London (UCL)
Jack Stroud is a clinical psychologist and psychedelic researcher whose work spans psilocybin, autism, and psychedelic-related changes in mental health and social functioning.
Michael Grunebaum
Associate Professor of Psychiatry at Columbia University Irving Medical Center; Research Psychiatrist at the New York State Psychiatric Institute
He is a leading ketamine and suicidality researcher whose clinical trials and meta-analytic work helped shape rapid-acting antidepressant research in psychiatry.
Erwin Krediet
Psychologist and psychedelic researcher at ARQ National Psychotrauma Centre; PhD researcher at Leiden University Medical Center
He is a Dutch psychedelic researcher contributing to clinical studies and educational work on psychedelics, including MDMA-assisted psychotherapy for PTSD and LSD/psilocybin studies.
David Hellerstein
Professor of Clinical Psychiatry at Columbia University Irving Medical Center; Research Psychiatrist at the New York State Psychiatric Institute; Director of the Depression Evaluation Service
He is a principal investigator on psilocybin studies for treatment-resistant depression and related psychiatric conditions, helping establish the clinical evidence base for psychedelic-assisted therapy.
Michael Mithoefer
Senior Medical Director for Medical Affairs at MAPS PBC
Conducted the first FDA-approved clinical trial of MDMA-assisted therapy for PTSD.
Connected Evidence
The latest clinical data and verified academic findings associated with Health Economics & Reimbursement.